Barvarian Nordic has again delayed (slightly) when they expect to have the initial results of the Phase III clinical trial of Prostvac in the treatment of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development | Tagged: mCRPC, outcome, Prostvac, result, trial | Leave a comment »
We already know that linking certain types of radioactive agent to specific forms of prostate-specific membrane antigen (PSMA) offers new opportunities for the treatment of challenging cases of prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: indium-111, photosensitizer, Treatment | 4 Comments »
Apparently the National Cancer Institute (NCI) has just re-funded the Fred Hutchinson Cancer Research Center in Seattle to the tune of $24 million to continue to operate what we see as an important, patient-centric program here in the USA that we (and therefore probably many others) were utterly unaware of. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: clinical, help, information, support, trials | 2 Comments »
Yesterday, the US Food & Drug Administration (FDA) did something it has never done before. It approved a drug for the treatment of a type of cancer based exclusively on the presence of a specific biomarker — with no reference to the location of the cancer in the patient’s body. … READ MORE …
Filed under: Drugs in development | Tagged: approval, biomarker, FDA, pembrolizumab | 8 Comments »
In January this year we had mentioned that a company called Churchill Pharmaceuticals was developing a new “submicron” formulation of abiraterone acetate. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abirateone, acetate, Churchill, FDA, Yonsa | 3 Comments »
The most frequent alteration in the prostate oncogenome is loss of chromosome (chr) 8p21 that has been associated with loss of NKX3.1 homeobox gene.
… READ MORE …
Filed under: Drugs in development | Tagged: EMT, expression, miR-3622a, transition | Leave a comment »
There are now two, ongoing, Phase III trials of PARP inhibitors in the treatment of eligible patients with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: inhibitor, mCRPC, PARP, Phase III, trial | Leave a comment »
